21st June 2019

The approval of immune checkpoint inhibitors has clearly revolutionised cancer therapy. Even so, there remains an urgent need to find treatments for patients that do not respond to or are not eligible to receive this class of drugs. Given this, many more innovative approaches are now being developed to re-direct the immune system towards tumour cells, ranging from small molecules and novel biologics to cell therapies and gene therapy approaches. We will bring together renowned experts from academia and industry to discuss the latest immunotherapy advances and highlight how these discoveries form the basis of novel drugs that are designed to target key immunology pathways and transform the lives of cancer patients. This meeting will be of interest to students and practicing professionals from academia and industry looking to gain an understanding of the pathological mechanisms at play within immune oncology and their targeting in discovery and development of novel immunotherapies. Please note that places are limited, so register early to avoid disappointment.